Lotemax SM®
loteprednol etabonate ophthalmic gel 0.38%
Clinical Snapshot
Lotemax SM delivers loteprednol via submicron particle technology for improved ocular surface distribution. It is FDA-approved for postoperative inflammation and widely used off-label for ocular surface inflammatory conditions.
Mechanism of Action
Submicron particle technology enhances drug penetration and distribution across the ocular surface. As a retrometabolic corticosteroid, loteprednol undergoes predictable inactivation, reducing systemic absorption and IOP-related risk while maintaining anti-inflammatory efficacy.
Common Clinical Applications
- Postoperative inflammation and pain following ocular surgery
- Off-label: short-term management of ocular surface inflammation
Typical Dosing Principles
One to two drops four times daily beginning 24 hours after surgery and continuing throughout the first 2 weeks of the postoperative period.
Dosing information is provided for educational purposes. Always consult current prescribing information for specific dosing protocols.
Important Precautions
- Contraindicated in most viral diseases of the cornea and conjunctiva.
- IOP should be monitored with extended use.
- Not for injection.
Clinical Pearls
- The submicron gel formulation is designed for improved ocular surface distribution and patient comfort.
- Retrometabolic design makes it a preferred corticosteroid when IOP risk is a concern.
- Shake well before use; the gel vehicle may cause transient blurred vision.
Commonly Associated Disease States
Select any disease state to explore its full entry in the Disease State Library.
Dry Eye Disease
One of the most prevalent conditions in optometric practice; a leading cause of patient dissatisfaction and reduced quality of life, with significant implications for contact lens wear, surgical candidacy, and systemic disease management.
Ocular Surface Optimization Before Surgery
Unoptimized ocular surface disease is a leading cause of refractive surprise and patient dissatisfaction after cataract and refractive surgery; preoperative surface optimization is a standard of care.
This entry is an educational reference designed to support clinical reasoning and therapeutic awareness. It does not constitute medical advice, establish a standard of care, or replace individualized patient assessment. Clinicians should consult current prescribing information before initiating any therapy.